ArticleOncology letters2015

Afzelin exhibits anti-cancer activity against androgen-sensitive LNCaP and androgen-independent PC-3 prostate cancer cells through the inhibition of LIM domain kinase 1.

Kai-Chang Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.